How Immunotherapies are Changing the Treatment of Melanoma

Special Reports, Immunotherapy (Issue 2), Volume 2, Issue 1

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.

Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.

Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >